# Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE

> **NCT03642561** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Fudan University** · enrollment: 300 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** radiotherapy ablation
- **DEVICE:** transarterial chemoembolization(TACE)

## Key facts

- **NCT ID:** NCT03642561
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-03
- **Primary completion:** 2022-08-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03642561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03642561, "Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03642561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*